Diabetes Care, Vol 20, Issue 11 1683-1687, Copyright © 1997 by American Diabetes Association

ARTICLES

U.K. Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex

OBJECTIVE: To compare fasting plasma lipids and lipoproteins in male and female patients at diagnosis of NIDDM and to examine age and sex differences in lipid concentrations. RESEARCH DESIGN AND METHODS: Cross-sectional study of fasting plasma total cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride in 2,139 male and 1,574 female white patients, aged 25-65 years, at diagnosis of NIDDM. RESULTS: At diagnosis of NIDDM, the mean age +/- SD for men was 52 +/- 9 and 53 +/- 9 years for women; BMI was 28.3 +/- 4.9 and 30.8 +/- 6.7 kg/m2, and fasting plasma glucose was 11.6 +/- 3.6 and 12.4 +/- 3.8 mmol/l, respectively. The mean total and LDL cholesterol were higher in female than in male NIDDM patients, 5.8 +/- 1.2 vs. 5.5 +/- 1.1 and 3.9 +/- 1.1 vs. 3.6 +/- 1.0 mmol/l (both P < 0.001), respectively, while triglyceride levels were similar: geometric mean (1 SD interval) for men and women was 1.8 (1.1-3.1) vs. 1.8 (1.1-2.9) mmol/l. HDL cholesterol was higher in female than in male NIDDM patients, 1.09 +/- 0.2 vs. 1.01 +/- 0.24 mmol/l (P < 0.001); the sex differential for HDL cholesterol was 7% in NIDDM patients compared with 22% in the general population. Data analysis by 5-year age bands showed a significant trend toward lower total cholesterol and triglyceride and higher HDL cholesterol in men diagnosed above the age of 50 years. In female NIDDM patients, lipid concentrations increased with age of diagnosis but reached a plateau above the age of 50 years. CONCLUSIONS: The effect of NIDDM, observed at diagnosis, on plasma lipid and lipoprotein levels is more pronounced in women than in men. This may explain in part why the cardiovascular risk is proportionally higher in female patients.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. Pedro-Botet Review: The role of fenofibrate in reducing cardiovascular risk in type 2 diabetes The British Journal of Diabetes & Vascular Disease, January 1, 2008; 8(1): 22 - 27. [Abstract] [PDF]

				H. N. Ginsberg REVIEW: Efficacy and Mechanisms of Action of Statins in the Treatment of Diabetic Dyslipidemia J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 383 - 392. [Abstract] [Full Text] [PDF]

				J. M. Lawrence, J. Reid, G. J. Taylor, C. Stirling, and J. P.D. Reckless Favorable Effects of Pioglitazone and Metformin Compared With Gliclazide on Lipoprotein Subfractions in Overweight Patients With Early Type 2 Diabetes Diabetes Care, January 1, 2004; 27(1): 41 - 46. [Abstract] [Full Text] [PDF]

				J.-L. Chiasson, R. G. Josse, R. Gomis, M. Hanefeld, A. Karasik, and M. Laakso Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance: The STOP-NIDDM Trial JAMA, July 23, 2003; 290(4): 486 - 494. [Abstract] [Full Text] [PDF]

				J. Valabhji and R. S Elkeles Dyslipidaemia in type 2 diabetes: epidemiology and biochemistry The British Journal of Diabetes & Vascular Disease, May 1, 2003; 3(3): 184 - 189. [Abstract] [PDF]

				R. A. Kreisberg and A. Oberman Lipids and Atherosclerosis: Lessons Learned from Randomized Controlled Trials of Lipid Lowering and Other Relevant Studies J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 423 - 437. [Full Text] [PDF]

				J. ARMITAGE and R. COLLINS Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials Heart, October 1, 2000; 84(4): 357 - 360. [Full Text]